Literature DB >> 16155144

Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis.

Mark E Mullins1, Glenn D Barest, Pamela W Schaefer, Fred H Hochberg, R Gilberto Gonzalez, Michael H Lev.   

Abstract

BACKGROUND AND
PURPOSE: Conventional MR imaging findings are considered to be inadequate for reliably distinguishing radiation necrosis from tumor recurrence in patients with glioma. Despite this belief, we hypothesized that certain conventional MR imaging findings, alone or in combination, though not definitive, may favor one or another of these diagnoses in proton beam-treated patients with new enhancing lesions on serial scanning.
METHODS: MR imaging findings (axial T1-, T2-, and post-gadolinium T1-weighted) of 27 proton beam radiation therapy patients with high-grade gliomas were retrospectively reviewed. Entry criteria included new MR imaging enhancing lesions after treatment and histologically unequivocal biopsy proof of diagnosis. Readers rated corpus callosum involvement, midline spread, subependymal spread, new discrete multiple enhancing foci, a "spreading wavefront" appearance, and septum pellucidum involvement. Statistical analysis was by the Fisher exact test.
RESULTS: Corpus callosum involvement in combination with multiple other findings was highly associated with progressive glioma. These combinations included involvement of the corpus callosum with multiple enhancing foci (P = .02), involvement of the corpus callosum with crossing the midline and multiple enhancing lesions (P = .04), and involvement of the corpus callosum with subependymal spread and multiple enhancing lesions (P = .01).
CONCLUSIONS: In proton beam-treated patients with glioma, corpus callosum involvement, in conjunction with multiple enhancing lesions with or without crossing of the midline and subependymal spread, favors predominant glioma progression. Overall, combinations of enhancement patterns were more likely than individual patterns to distinguish necrosis from predominant tumor progression. Together with clinical and functional imaging findings, these results may assist in determining the need for biopsy.

Entities:  

Mesh:

Year:  2005        PMID: 16155144      PMCID: PMC8148818     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  15 in total

1.  Diffusion weighted imaging in radiation necrosis.

Authors:  V Biousse; N J Newman; S B Hunter; P A Hudgins
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

Review 2.  Dynamic susceptibility contrast MRI of gliomas.

Authors:  Hannu J Aronen; Jussi Perkiö
Journal:  Neuroimaging Clin N Am       Date:  2002-11       Impact factor: 2.264

Review 3.  Positron emission tomography imaging of brain tumors.

Authors:  Terence Z Wong; Gert J van der Westhuizen; R Edward Coleman
Journal:  Neuroimaging Clin N Am       Date:  2002-11       Impact factor: 2.264

4.  The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery.

Authors:  S T Chao; J H Suh; S Raja; S Y Lee; G Barnett
Journal:  Int J Cancer       Date:  2001-06-20       Impact factor: 7.396

5.  Cerebral radionecrosis: incidence and risk in relation to dose, time, fractionation and volume.

Authors:  J E Marks; R J Baglan; S C Prassad; W F Blank
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-02       Impact factor: 7.038

6.  Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment.

Authors:  A J Kumar; N E Leeds; G N Fuller; P Van Tassel; M H Maor; R E Sawaya; V A Levin
Journal:  Radiology       Date:  2000-11       Impact factor: 11.105

Review 7.  Dynamic contrast-enhanced brain perfusion imaging: technique and clinical applications.

Authors:  F G Aksoy; M H Lev
Journal:  Semin Ultrasound CT MR       Date:  2000-12       Impact factor: 1.875

8.  Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: results of an institutional phase I/II trial.

Authors:  M M Fitzek; A F Thornton; G Harsh; J D Rabinov; J E Munzenrider; M Lev; M Ancukiewicz; M Bussiere; E T Hedley-Whyte; F H Hochberg; F S Pardo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-09-01       Impact factor: 7.038

9.  PET and SPECT for detection of tumor progression in irradiated low-grade astrocytoma: a receiver-operating-characteristic analysis.

Authors:  Marcus Henze; Ashour Mohammed; Heinz P Schlemmer; Klaus K Herfarth; Simone Hoffner; Sabine Haufe; Walter Mier; Michael Eisenhut; Jürgen Debus; Uwe Haberkorn
Journal:  J Nucl Med       Date:  2004-04       Impact factor: 10.057

Review 10.  Imaging of irradiated brain tumours. Value of magnetic resonance imaging.

Authors:  J C Castel; J M Caillé
Journal:  J Neuroradiol       Date:  1989       Impact factor: 3.447

View more
  77 in total

1.  Support vector machine multiparametric MRI identification of pseudoprogression from tumor recurrence in patients with resected glioblastoma.

Authors:  Xintao Hu; Kelvin K Wong; Geoffrey S Young; Lei Guo; Stephen T Wong
Journal:  J Magn Reson Imaging       Date:  2011-02       Impact factor: 4.813

2.  Development of a novel animal model to differentiate radiation necrosis from tumor recurrence.

Authors:  Sanath Kumar; Ali S Arbab; Rajan Jain; Jinkoo Kim; Ana C deCarvalho; Adarsh Shankar; Tom Mikkelsen; Stephen L Brown
Journal:  J Neurooncol       Date:  2012-03-10       Impact factor: 4.130

Review 3.  Imaging radiation response in tumor and normal tissue.

Authors:  Marjan Rafat; Rehan Ali; Edward E Graves
Journal:  Am J Nucl Med Mol Imaging       Date:  2015-06-15

Review 4.  Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging.

Authors:  Rajan Jain; Jayant Narang; Pia M Sundgren; David Hearshen; Sona Saksena; Jack P Rock; Jorge Gutierrez; Tom Mikkelsen
Journal:  J Neurooncol       Date:  2010-02-24       Impact factor: 4.130

5.  Computer-Extracted Texture Features to Distinguish Cerebral Radionecrosis from Recurrent Brain Tumors on Multiparametric MRI: A Feasibility Study.

Authors:  P Tiwari; P Prasanna; L Wolansky; M Pinho; M Cohen; A P Nayate; A Gupta; G Singh; K J Hatanpaa; A Sloan; L Rogers; A Madabhushi
Journal:  AJNR Am J Neuroradiol       Date:  2016-09-15       Impact factor: 3.825

6.  Bevacizumab in the treatment of radiation injury for children with central nervous system tumors.

Authors:  Nathan A Dahl; Arthur K Liu; Nicholas K Foreman; Melissa Widener; Laura Z Fenton; Margaret E Macy
Journal:  Childs Nerv Syst       Date:  2019-07-31       Impact factor: 1.475

Review 7.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

8.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

9.  Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.

Authors:  Ramon F Barajas; Bronwyn E Hamilton; Daniel Schwartz; Heather L McConnell; David R Pettersson; Andrea Horvath; Laszlo Szidonya; Csanad G Varallyay; Jenny Firkins; Jerry J Jaboin; Charlotte D Kubicky; Ahmed M Raslan; Aclan Dogan; Justin S Cetas; Jeremy Ciporen; Seunggu J Han; Prakash Ambady; Leslie L Muldoon; Randy Woltjer; William D Rooney; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2019-03-18       Impact factor: 12.300

10.  Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.

Authors:  Eiji Matsusue; James R Fink; Jason K Rockhill; Toshihide Ogawa; Kenneth R Maravilla
Journal:  Neuroradiology       Date:  2009-10-16       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.